



RECEIVED

JUN 28 2001

AF 1643/9

TECH CENTER 1600/2900

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/511,582	
	Filing Date	February 23, 2000	
	First Named Inventor	Jan Raa	
	Group Art Unit	1643	
	Examiner Name	Jeffery Stucker	
Total Number of Pages in This Submission	11	Attorney Docket Number	CU-2140 TJK

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Stamped self-addressed receipt postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	David A. Frey, Reg No. 43,618, Wildman Harrold Allen & Dixon
Signature	
Date	June 20, 2001

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: <u>June 20, 2001</u>			
Typed or printed name	Elvia Olguin		
Signature		Date	6/20/01

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

JUN 28 2001

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

TECH CENTER 1600/2900

In re Patent Application of:

Jan Raa et al.

Atty. Docket No. CU-2140 TJK

Serial No. 09/511,582

Group Art Unit: 1643

Filing Date: February 23, 2000

Examiner: Jeffery Stucker

Title: NOVEL, NON-ANTIGENIC, MUCOSAL ADJUVANT FORMULATION WHICH MODULATES THE EFFECTS OF SUBSTANCES, INCLUDING VACCINE ANTIGENS, IN CONTACT WITH MUCOSAL BODY SURFACES

Wildman, Harrold, Allen & Dixon
225 W. Wacker Dr.
Suite 3000
Chicago, IL 60606-1229

BOX AF

Hon. Commissioner of Patents & Trademarks
Washington, D.C. 20231

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for patents, Washington, D.C. 20231 on

AMENDMENT

6/20/01
[Signature]

Sir:

This is in response to the Office Action dated February 20, 2001. Please amend as follows:

IN THE SPECIFICATION:

On page 2, line 9 replace the second paragraph with the following:

Mucosal vaccines are rising in popularity on a global scale due in part to ease of administration of these vaccines as opposed to subcutaneous or other traditional means of administration, the ease in facilitating self administration of mucosal vaccines as opposed to the traditional delays associated with assembling masses of people for traditional vaccine administration, as well as the reduction and eventual elimination of hypodermic needles. An